21.961 articles found

N-ALKYL-N-PHENYLHYDROXYLAMINE COMPOUNDS CONTAINING METAL CHELATING GROUPS, THEIR PREPARATION AND THEIR THERAPEUTIC USES

OH EU-GENE, KO SUNG-BO, KIM WON-YEOB, KIM KYUNG-HWA, CHOI DENNIS W, DUGAN LAURA L, KANG TAE-CHEON, KOH JAE-YOUNG, KIM KYOUNG-MI, SHIN IN-JAE.

· 2001-07-26

APORPHINE ESTERS AND THEIR USE IN THERAPY

WIKSTROM HAKAN, DIJKSTRA DURK, CREMERS THOMAS, ANDREN PER ERIK, MARCHAIS SANDRINE, JURVA ULRIK.

· 2001-07-20

AGENT FOR PARKINSON DISEASE TREATMENT CONTAINING COMPOUND IMPROVING ASTROCYTE FUNCTION AS ACTIVE INGREDIENT

ITOJAMA JASUTO, KATO KHIROJUKI, ARAKI TSUTOMU.

· 2001-07-17

THERAPEUTIC AGENT FOR PARKINSON'S DISEASE INCLUDING FUNCTION IMPROVING AGENT FOR ASTROCYTE.

TSUTOMU ARAKI.

· 2001-07-16

Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the pathogenesis and treatment of Parkinson's disease.

Volles MJ, Lee SJ, Rochet JC, Shtilerman MD, Ding TT, Kessler JC, Lansbury PT.

Biochemistry · 2001-07-01

DOI: 10.1021/bi0102398PMID: 11425308

Initial treatment of Parkinson's disease: wait just a minute.

Check source for author details

Med Lett Drugs Ther · 2001-07-01

PMID: 11445778

Dopamine D5 receptor gene polymorphism and the risk of levodopa-induced motor fluctuations in patients with Parkinson's disease.

Wang J, Liu ZL, Chen B.

Neurosci Lett · 2001-07-01

DOI: 10.1016/s0304-3940(01)01971-1PMID: 11445276

Levodopa pharmacokinetic-pharmacodynamic modeling and 6-[18F]levodopa positron emission tomography in patients with Parkinson's disease.

Dietz M, Harder S, Graff J, Künig G, Vontobel P, Leenders KL, Baas H.

Clin Pharmacol Ther · 2001-07-01

DOI: 10.1067/mcp.2001.116328PMID: 11452242

Xenotransplantation for brain repair: reduction of porcine donor tissue immunogenicity by treatment with anti-Gal antibodies and complement.

Brevig T, Meyer M, Kristensen T, Zimmer J, Holgersson J.

Transplantation · 2001-07-01

DOI: 10.1097/00007890-200107270-00004PMID: 11477337

Comparison of two dosages of tolcapone added to levodopa in nonfluctuating patients with PD.

Suchowersky O, Bailey P, Pourcher E, Bulger L, Facciponte G.

Clin Neuropharmacol · 2001-07-01

DOI: 10.1097/00002826-200107000-00004PMID: 11479392

Influence of the dopamine agonist alpha-dihydroergocryptine on the pharmacokinetics of levodopa in patients with Parkinson's disease.

Minea D, Varga I, Falup-Pecurariu C, de Mey C, Retzow A, Althaus M.

Clin Neuropharmacol · 2001-07-01

DOI: 10.1097/00002826-200107000-00008PMID: 11479396

Antiparkinsonian activity and dyskinesia risk of ropinirole and L-DOPA combination therapy in drug naïve MPTP-lesioned common marmosets (Callithrix jacchus).

Maratos EC, Jackson MJ, Pearce RK, Jenner P.

Mov Disord · 2001-07-01

DOI: 10.1002/mds.1149PMID: 11481686